Impact of screening blood donors for hepatitis C antibody on posttransfusion hepatitis: a prospective study with a second-generation anti-hepatitis C virus assay

Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan

To determine the hepatitis C virus (HCV) genotype distribution in Taiwan and to clarify the relationship between genotype and the pathogenesis of HCV infection, 1,164 subjects positive for serum HCV antibodies and HCV RNA from three HCV hyperendemic areas (Masago, Tzukuan, and Taoyuan) and a tertiary referral center in Taiwan were studied during 1995-1997. HCV genotypes and viral loads were determined using Okamoto's method and branched DNA assay, respectively. Genotype 1b was the most prevalent in Tzukuan (61.9%), Taoyuan (76.9%), and the referral center (47.0%). By contrast, genotype 2a was the major HCV type in Masago (63.5%). Prevalence of genotype 1b positively and that of genotype 2a negatively correlated to age, regardless of study populations (P < 0.01). Based on multivariate analysis, the significant factors associated with the presence of cirrhosis, with or without hepatocellular carcinoma, in chronic hepatitis C patients were genotype 1b and age. In conclusion, these results underline that independent HCV outbreaks continue in HCV hyperendemic areas in Taiwan, concomitant with a changing relative prevalence of HCV genotypes in relation to age. Both the correlation of genotype 1b with age (cohort effect) and intrinsic properties of HCV genotypes are probably responsible for the association between genotype and the pathogenesis of HCV infection.

TT viral infection through blood transfusion: retrospective investigation on patients in a prospective study of post-transfusion hepatitis

AIM: To investigate the role of blood transfusion in TT viral infection (TTV).

METHODS: We retrospectively studied serum samples from 192 trans fusion recipients who underwent cardiovascular surgery and blood transfusion between July 1991 and June 1992. All patients had a follow-up every other week for at least 6 months after transfusion. Eighty recipients received blood before screening donors for hepatitis C antibody (anti-HCV), and 112 recipients received screened blood. Recipients with alanine aminotransferase level > 2.5 times the upper normal limit were tested for serological markers for viral hepatitis A, B, C, G, Epstein Barr virus and cytomegalovirus. TTV infection was defined by t he positivity for serum TTV DNA using the polymerase chain reaction method.

RESULTS: Eleven and three patients, who received anti-HCV uns creened and screened blood, respectively, had serum ALT levels > 90 IU/L. Five patients (HCV and TTV:1; HCV, HGV, and TTV:1; TTV:2; and CMV and TTV:1 ) were positive for TTV DNA, and four of them had sero-conversion of TTV DNA.

CONCLUSION: TTV can be transmitted via blood transfusion. Two recipients infected by TTV alone may be associated with the hepatitis. However, whether TTV was the causal agent remains unsettled, and further studies are necessary to define the role of TTV infection in chronic hepatitis.

Post-transfusion hepatitis type B following multiple transfusions of HBsAg-negative blood

BACKGROUND/AIMS

Post-transfusion hepatitis continues to occur, though with decreasing frequency, even after screening donor blood for HBsAg, anti-HBc, anti-HCV and alanine aminotransferase activity. Data from developing countries on the frequency and type of post-transfusion hepatitis are scarce. We undertook this prospective study to determine the incidence and type of post-transfusion hepatitis at our center after transfusion of blood negative for HBsAg by ELISA.

METHODS

Forty-one patients undergoing open-heart surgery, who had received 3 or more units of HBsAg-negative blood, were followed up. Serum samples of donor units transfused to recipients who developed post-transfusion hepatitis-B were subjected to HBV DNA amplification by the polymerase chain reaction, using two sets of X-gene specific primers which amplified a 250-bp fragment of the HBV DNA.

RESULTS

We found that six of the 41 patients (14.6%) developed post-transfusion hepatitis; four of them (66.6%) developed icteric post-transfusion hepatitis B, whereas two (33.3%) developed anicteric post-transfusion hepatitis C. These six recipients received a total of 48 units of blood and 30 of these 48 units could be subjected to HBV DNA amplification by polymerase chain reaction. Eleven donor samples were polymerase chain reaction positive and had been transfused to three of the four patients who had developed post-transfusion hepatitis B.

CONCLUSIONS

We conclude that post-transfusion hepatitis B continues to be the most common cause of post-transfusion hepatitis in India. Screening of donor units for HBsAg by ELISA does not exclude all blood units infectious for hepatitis B virus. Additional measures to ensure safety of blood supply should be sought.

Transmission of hepatitis C virus by a cardiac surgeon

BACKGROUND

In the course of a study conducted in 1992 through 1994 of the efficacy of screening blood donors for antibodies to hepatitis C virus (HCV), we found that two patients had acquired hepatitis C after cardiac surgery, with the transmission apparently unrelated to blood transfusions. Because their surgeon had chronic hepatitis C, we sought to determine whether he was transmitting the virus to his patients.

METHODS

Of 222 of the surgeon's patients who participated in studies of post-transfusion hepatitis between 1988 and 1994, 6 contracted postoperative hepatitis C, despite the use of only seronegative blood for transfusions. All six patients had undergone valve-replacement surgery. Analyses were performed to compare nucleotide sequences encompassing the hypervariable region at the junction between the coding regions for envelope glycoproteins E1 and E2 in the surgeon, the patients, and 10 controls infected with the same HCV genotype.

RESULTS

The surgeon and five of the six patients with hepatitis C unrelated to transfusion were infected with HCV genotype 3; the sixth patient had genotype 1 and was considered to have been infected from another source. Thirteen other patients of the surgeon had transfusion-associated hepatitis C and were also infected with genotype 1. The average net genetic distance between the sequences from the five patients with HCV genotype 3 and those from the surgeon was 2.1 percent (range, 1.1 to 2.5 percent; P < 0.001), as compared with an average distance of 7.6 percent (range, 6.1 to 8.3 percent) between the sequences from the patients and those from the controls. The results of phylogenetic-tree analysis indicated a common epidemiologic origin of the viruses from the surgeon and the five patients.

CONCLUSIONS

Our findings provide evidence that a cardiac surgeon with chronic hepatitis C may have transmitted HCV to five of his patients during open-heart surgery.

Prevalence of hepatitis C virus in plasma pools and the effectiveness of cold ethanol fractionation

Screening blood donations for antibodies against hepatitis C virus (HCV) greatly reduces the risk of transmitting HCV by transfusions. However, despite such screening programs, plasma pools still contain a high percentage of HCV ribonucleic acid as determined by polymerase chain reaction. This result would not be alarming if the procedures for producing blood products included steps to inactivate or remove HCV. Although this appeared to be the case for all blood products, such as coagulation factors and most immunoglobulins, which are subjected to an inactivation step, the effectiveness of the cold ethanol fractionation process still needed to be determined. In validation experiments using bovine viral diarrhea virus as a model virus for HCV, we demonstrated that the Cohn-Oncley cold ethanol fractionation process neither inactivated nor removed this virus sufficiently. Our observations may help to explain how HCV was transmitted to a number of recipients of intravenous immunoglobulin.

Effect of hepatitis C antibody screening in blood donors on post-transfusion hepatitis in Taiwan

A national screening programme for antibody to hepatitis C virus (HCV) in blood donors in Taiwan began in July 1992 using a second-generation immunoassay. To study the impact of this screening on post-transfusion hepatitis in Taiwan, a prospective study on post-transfusion hepatitis, that was started in 1987, was continued. As of June 1994, 245 patients who received a blood transfusion after July 1992 had completed a follow-up period for more than 6 months post-transfusion. Of them, seven (2.8%) recipients developed acute post-transfusion hepatitis. The hepatitis in six cases could not be attributed to infection by hepatitis A, B, C, D, E viruses or cytomegalovirus (CMV) or Epstein-Barr virus (EBV). The remaining patient seroconverted to both IgG and IgM anti-CMV. All seven patients recovered in 6 months without development of chronicity, and the mean peak alanine aminotransferase level was lower compared with that of the cases before anti-HCV screening (i.e. pre-July 1992). These results indicate that the current anti-HCV screening has effectively interrupted HCV transmission through blood transfusion in Taiwan.